Skip to main content

Analysts Caution Against Overreacting To Biogen's Alzheimer's Trial Change

Biogen said the company has decided to add 510 patients to the Phase 3 aducanumab trials after seeing more "variability" than expected in a sample size re-estimation, sending its shares into negative territory.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.